Autopsy report · NCT01514734

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

“Low recruitment rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 5 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Alcon Research

Sponsor type

Industry

Conditions

Glaucoma

Interventions

Brinzolamide/timolol maleate fixed combination

Participants

9

Sites

1

Countries

Brazil

Trials that died the same way

• NHFOV Versus NCPAP to Prevent Exubation Failure
  “Poor recruitment rate” (95% match in meaning)
• Whole-body Vibration Physiotherapy in Kidney Transplantation
  “Due to low recruitment rate” (90% match in meaning)
• Cerebral Autoregulation in Non Neurological Critical Patients.
  “Slow recruitment rate” (89% match in meaning)
• Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
  “low recruitment” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.